FDA postpones key hearing on biosimilar copy of blockbuster drug

(Reuters) - The U.S. Food and Drug Administration has postponed a crucial meeting of an advisory committee to consider a cheap version of a top-selling drug for rheumatoid arthritis and Crohn's disease, which had been scheduled for March 17.

Source: Reuters: Health - February 26, 2015 Category: Consumer Health News Tags: healthNews Source Type: news